Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD
NCT04247594
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
6
Enrollment
INDUSTRY
Sponsor class
Stopped
Data will not inform further development of Voxelotor
Conditions
Sickle Cell Disease
Interventions
DRUG:
Voxelotor
Sponsor
Pfizer